-0.26 (-6.06%)
Dilution Risk
R&D Expenses
5.41 M
Total Assets
10.26 M
Total Liabilities
4.38 M
Equity
5.88 M
D/E Ratio
12,345
Cash Position
2.94 M
Monthly Burn
2.42 M
Runway
0 mo
Burn Trend
StableSEC Filing
Feb 17, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Modular Medical, Inc. has announced the pricing of a registered direct offering of 750,000 shares of common stock at $4.50 each, expected to generate around $3.4 million. The offering is set to close on or about April 21, 2026, pending customary closing conditions. Maxim Group LLC is the sole placement agent for this offering.
Read more →Modular Medical, Inc. has announced that it has successfully regained compliance with the Nasdaq Capital Market's minimum bid price requirement. As of April 14, 2026, the company's common stock has maintained a closing bid price exceeding $1.00 for 10 consecutive trading days. Nasdaq has confirmed that the matter is now closed. Modular Medical aims to innovate in insulin delivery technology, making it both affordable and user-friendly.
Read more →Modular Medical, Inc. has announced a 1-for-30 reverse stock split of its common stock, effective March 31, 2026. This decision was made to satisfy Nasdaq's minimum bid price requirement of $1.00 per share, following approval from shareholders at the fiscal 2026 Annual Meeting. Post-split, approximately 4.66 million shares will remain outstanding. The change is aimed at improving the company's financial standing and market perception. Shareholders will receive cash for any fractional shares resulting from the split.
Read more →Modular Medical, Inc. has announced a $12.0 million public offering priced at $0.1762 per share, aimed at new and existing investors. The offering includes 68,098,000 shares and warrants exercisable immediately. The expected gross proceeds may enhance the company's financial position as it prepares for the closing, scheduled around March 4, 2026. Maxim Group LLC serves as the sole placement agent for this offering.
Read more →Modular Medical has commenced production of validation lots for its Pivot tubeless insulin patch pump, aiming for a Q1 2026 launch pending FDA clearance. The Pivot system targets adults with diabetes who are reluctant to switch from multiple daily injections due to cost and complexity. This milestone is expected to enhance the company's scalability and market position in the growing diabetes tech sector.
Read more →Modular Medical, Inc. has been granted a 180-day extension by Nasdaq to comply with the minimum bid price requirement. The company must achieve a closing bid price of $1.00 per share for 10 consecutive business days by June 29, 2026, to regain compliance. If unsuccessful, it risks delisting but can appeal any decision made by Nasdaq.
Read more →Modular Medical, Inc. has announced a proposed public offering of its common stock and warrants to expand its operations. The offering is targeted at adult diabetics and is expected to improve access to innovative insulin delivery technology. While the company has initiated this offering to potentially enhance funding and growth, it also noted the uncertainties surrounding its completion and market conditions. The offering is backed by Newbridge Securities Corporation as the sole bookrunner and follows a previously effective registration statement.
Read more →Modular Medical has announced the appointment of Jeff Goldberg to its Board of Directors. Goldberg, an established industry veteran, brings significant experience in healthcare and medical devices, particularly in developing generic insulin. His leadership is anticipated to support Modular Medical's goals of simplifying insulin delivery and enhancing diabetes care. The company aims to provide affordable and effective insulin delivery solutions, with Goldberg playing a crucial role in this vision.
Read more →Modular Medical, Inc. has announced that the U.S. FDA has cleared its MODD1 insulin pump for marketing and sale in the United States. The company is focusing on making diabetes care more accessible and affordable, particularly for underserved communities. With commercial manufacturing nearly complete, the MODD1 pump is expected to be available for consumers in early 2025. The leadership expresses gratitude to employees and shareholders, emphasizing their commitment to improving diabetes care.
Read more →Modular Medical, Inc. announced a proposed public offering of its common stock to support its development of next-generation insulin delivery technology. The offering includes a 30-day option for the underwriter to purchase additional shares, but it remains subject to market conditions. The company, led by experienced professionals in medical devices, aims to improve access to insulin delivery systems, although uncertainty exists regarding the completion and terms of the offering. This step is crucial for financing further product development against various market risks.
Read more →Modular Medical has announced the submission of its MODD1 insulin pump for 510(k) clearance to the FDA, marking a significant step in its product development. The company is focused on creating a user-friendly and affordable device to enhance diabetes management. The pump's design aims to attract users who have been deterred by the complexity and cost of existing insulin pumps. Additionally, Modular Medical plans to pursue UKCA mark clearance while preparing for market launch.
Read more →Modular Medical, a development stage medical device company, is presenting its innovative insulin delivery system, MODD1, aimed at expanding access for diabetes management. The company plans to submit for FDA approval in January 2024 and targets a $3 billion market. The presentation highlights both the potential benefits of their product and the inherent risks associated with their forward-looking statements, particularly in relation to regulatory compliance and market acceptance. The company acknowledges the complexities and high costs of existing insulin pump systems as significant barriers to adoption among patients.
Read more →Modular Medical announced the appointment of Duane DeSisto to its board of directors. DeSisto, a veteran in the diabetes industry with over 25 years of experience, previously led Insulet Corporation during its significant growth. His expertise is expected to aid Modular Medical as it prepares to launch a new insulin delivery technology aimed at improving patient accessibility and outcomes. The leadership team believes this addition will provide strategic advantages in the competitive diabetes market.
Read more →Modular Medical, Inc. has announced the pricing of an upsized public offering totaling $9.4 million, consisting of shares and warrants. The net proceeds, estimated at about $8.3 million, are intended to support corporate operations and the anticipated FDA approval process for its insulin delivery technology. The offering, managed by Newbridge Securities Corporation, is set to close around May 18, 2023. Modular Medical aims to streamline insulin delivery and improve access for individuals managing diabetes.
Read more →Medical Appoints Kevin Schmid as Chief Operating Officer brings 40 years of experience in medical devices for drug delivery and diabetes management and a background in high-volume manufacturing Diego, CA / ACCESSWIRE / July 26, 2022 / Modular Medical, Inc. (the "Company" or "M
Read more →Investor Presentation . NASDAQ:MODD 2 | Forward Looking Statements, Other Disclaimers . This presentation includes forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d; Section 21E of the Securities Exchange Act of 1934, as am
Read more →Modular Medical Announces $8 Million Registered Direct Offering DIEGO, CA / ACCESSWIRE / May 3, 2022 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), today announced that it has entered into a securities purchase agreement with institutional investor
Read more →Modular Medical Appoints James "Jeb" Besser as Chief Executive Officer Lynn Vos to remain on board of directors Besser brings 25 years of experience in life sciences, technology, capital markets Company reaffirms timeline for 510(k) submission of MODD1 insulin pump to FDA Feb
Read more →Investor Presentation. Forward Looking Statements, Other Disclaimers. THIS SUMMARY IS PROVIDED ON A CONFIDENTIAL AND LIMITED BASIS, SOLELY FOR YOUR USE AS A PART OF YOUR DETERMINATION OF WHETHER TO INVEST IN THE OPPORTUNITY. THIS SUMMARY IS BEING PROVIDED IN RELIANCE UPON SECTI
Read more →Medical Announces Pricing of $15 Million Public Offering and Uplisting to the Nasdaq Capital Market DIEGO, CA, Feb. 10, 2022 (ACCESSWIRE) -- Modular Medical, Inc., (Nasdaq:MODD) (the "Company" or "Modular Medical"), a development-stage insulin pump company focused on providing
Read more →Felsher and Philip B. Sheibley Appointed to Board of Directors of Diego, CA, November 29, 2021 - Modular Medical, Inc. (the "Company" or "Modular Medical") (OTCQB:MODD), a development-stage insulin pump company focused on providing insulin delivery without complexity to increa
Read more →Inc. Announces Reverse Stock Split in Connection with Application for Uplisting on the NASDAQ Capital Market Diego, CA, November 26, 2021 - Modular Medical, Inc. (the "Company") (OTCQB:MODD), a development-stage insulin pump company focused on providing insulin delivery withou
Read more →Investor Presentation. OTCQB:MODD Forward Looking Statements, Other Disclaimers. THIS SUMMARY IS PROVIDED ON A CONFIDENTIAL AND LIMITED BASIS, SOLELY FOR YOUR USE AS A PART OF YOUR DETERMINATION OF WHETHER TO INVEST IN THE OPPORTUNITY. THIS SUMMARY IS BEING PROVIDED IN RELIANCE
Read more →EXPANDS EXECUTIVE TEAM WITH APPOINTMENT OF Vos Brings Deep Experience in Market Development, Products and Patient Advocacy / ACCESSWIRE /August 16, 2021 / Modular Medical, Inc. (OTCQB:MODD), a development-stage insulin pump company focused on providing insulin delivery withou
Read more →Medical Announces Financing SAN DIEGO, CA May 12, 2021 - Modular Medical, Inc. (OTCQB: MODD), a medical device company focused on next generation insulin delivery technologies to widen the accessibility of insulin pumps to a greater share of people with type 1 and type 2 diabete
Read more →Investor Presentation. Forward Looking Statements, Other Disclaimers. THIS SUMMARY IS PROVIDED ON A CONFIDENTIAL AND LIMITED BASIS, SOLELY FOR YOUR USE AS A PART OF YOUR DETERMINATION OF WHETHER TO INVEST IN THE OPPORTUNITY. THIS SUMMARY IS BEING PROVIDED IN RELIANCE UPON SECTI
Read more →STOCK PURCHASE AGREEMENT Common Stock Purchase Agreement (this "Agreement") is dated as of November 19, 2018, by and among MODULAR MEDICAL, INC., a Nevada corporation (the "Company"), and each investor listed on the Schedule of Investors attached hereto (individually an "Inves
Read more →Yu and Associates, Inc. Ventura Blvd., suite 316 (818)789-0265 Fax (818) 789-3949 Independent Registered Public Accounting Firm the accompanying balance sheets of Quasuras, Inc. (the "Company") as of March 31, 2017 and 2016, and the related statements of operations, stockhol
Read more →